Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -9K | -8K | 0 | 0 | -16K |
| Operating Income | -80K | -67K | -85K | -220K | -213K |
| EBITDA | 308K | 403K | -85K | 897K | -91K |
| Net Income | 238K | 723K | -188K | -4K | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.017
+0.00% today
1Y Change
-14.29%
Window
Jun 20, 2025 → May 29, 2026
Coverage: 237 bars · Jun 20, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
United American Healthcare Corporation (UAHC) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 14.3% across the available one-year price window (Jun 20, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -67.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -67.7%, free cash flow 0.0% with operating margin 0.0% and ROIC -5.6%. Valuation is more restrained than many high-expectation growth names at P/E 5.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UAHC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UAHC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UAHC Max Drawdown
-65.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UAHC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.6M
-65975.0% YoY
Free Cash Flow
$2.1M
+222.7% YoY
Revenue Growth
+0.0%
EPS Growth
-67.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -9K | -8K | 0 | 0 | -16K |
| Operating Income | -80K | -67K | -85K | -220K | -213K |
| EBITDA | 308K | 403K | -85K | 897K | -91K |
| Net Income | 238K | 723K | -188K | -4K | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 374K | 9M | 8M | 7M | 13M |
| Total Assets | 1M | 10M | 10M | 10M | 17M |
| Total Liabilities | 89K | 119K | 51K | 139K | 7M |
| Shareholder Equity | 1M | 10M | 10M | 10M | 10M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -374K | -9M | -8M | -7M | -13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+207.1% YoY
Capital Expenditures
19K
+52.5% YoY
Free Cash Flow
2M
+222.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
4.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.